1742. Kinetics of CMV Viremia with Letermovir Prophylaxis in the First 100 Days post Hematopoietic Cell Transplantation (HCT): A Single-center Experience

BACKGROUND: Letermovir (LTV) is approved for the prevention of CMV infection in CMV seropositive (R+) HCT recipients. Low rates of CMV breakthrough viremia have been reported with LTV prophylaxis. We studied the kinetics of CMV reactivation up to day (D) +100 in patients (patients) receiving LTV pro...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Open Forum Infect Dis
Egile Nagusiak: Zavras, Phaedon D, Stern, Anat, Su, Yiqi, Fang, Jiaqi, Giralt, Sergio, Perales, Miguel, Maloy, Molly, Seo, Susan K, Papanicolaou, Genovefa
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809059/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1605
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak